Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double‐blind, randomized, placebo‐controlled trial
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective: Allopurinol, a hypouricemic agent, has been shown to present therapeutic effects in mania associated with hyperuricemia. This study assessed the efficacy and safety of risperidone as an adjunctive agent to lithium and haloperidol for the treatment of acute mania in hospitalized bipolar patients. Methods: Eighty‐two patients aged between 18 and 49 were eligible to participate, as they met the DSM‐IV criteria for a current manic episode, on the basis of a clinical interview by two academician psychiatrists. In addition, a score of at least 20 points on the Young Mania Rating Scale was required representing at least a moderate‐to‐severe mania. Forty‐one patients were randomly allocated to lithium (1–1.2 mEq/L) + haloperidol (10 mg/day) + allopurinol (300 mg/day) (group A) or lithium (1–1.2 mEq/L) + haloperidol (10 mg/day) + placebo (group B) for an 8‐week, double‐blind, placebo‐controlled study. Patients were assessed by a third‐year resident of psychiatry at baseline and at 7, 14, 28, 42, and 56 days after the medication started. The mean decrease in the Young Mania Rating Scale score from baseline was used as the main outcome measure of response of mania to treatment. The extrapyramidal symptoms were assessed using the Extrapyramidal Symptoms Rating Scale (ESRS). Side effects were systematically recorded throughout the study and were assessed using a checklist. Results: Young Mania Rating Scale scores improved with allopurinol. The difference between the two protocols was significant as indicated by the effect of the group, the between‐subjects factor (F = 5.22, df = 1, p = 0.008). The mean ESRS scores for the placebo group were higher than the allopurinol group. However, the differences were not significant over the trial. The difference between the two groups in the frequency of side effects was not significant except for agitation that was more often in the placebo group. Conclusions: The efficacy of allopurinol to obtain a greater improvement in patients with mania seems to support the purinergic dysfunction in mania.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lyoo, I. K., Demopulos, C. M., Hirashima, F., Ahn, K. H., & Renshaw, P. F. (2003) · Bipolar Disorders · doi:10.1034/j.1399-5618.2003.00041.x · Cited by 33
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Yatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
de Melo, L. G. P., Nunes, S. O. V., Anderson, G., Vargas, H. O., Barbosa, D. S., Galecki, P., Carvalho, A. F., & Maes, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.027 · Cited by 189
Saroukhani, S., Emami‐Parsa, M., Modabbernia, A., Ashrafi, M., Farokhnia, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Bipolar Disorders · doi:10.1111/bdi.12108 · Cited by 59
Self-citation
Metadata
- Authors
- Akhondzadeh, S., Milajerdi, M. R., Amini, H., & Tehrani‐Doost, M.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2006-10
- Volume
- 8
- Issue
- 5p1
- Pages
- 485-489
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W2060883428
- Cited by
- 78
- References
- 1
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double‐blind, randomized, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/j.1399-5618.2006.00363.x
- The paper
- Akhondzadeh, S., Milajerdi, M. R., Amini, H., & Tehrani‐Doost, M. (2006). Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double‐blind, randomized, placebo‐controlled trial. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2006.00363.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.